Search the Newsreel

Earnings call transcript: Cricut tops EPS forecast in Q2 2026 as revenue slips

CRISPR Therapeutics AG Stock 12‑Month Price Target Raised to $84.39, Implies 70% Upside

The average 12-month price target for CRISPR Therapeutics AG (CRSP) stock has been raised to $84.39 from $83.94, based on estimates from 18 analysts. This updated target implies a potential upside of approximately 70% from its Aug. 3 closing price. The consensus rating among …

Crinetics Pharmaceuticals stock hits all-time high at 84.01 USD

Crinetics Pharmaceuticals' stock has reached an all-time high of $84.01, driven by a 187.21% increase over the past year and a market capitalization of $8.85 billion. This surge in value comes as Vertex Pharmaceuticals announced an agreement to acquire Crinetics for approximately $10 billion, …

Cricut (CRCT) insider files Form 144 to sell 60,000 Class A shares

Cricut insider Ashish Arora has filed a Form 144, indicating an intent to sell 60,000 Class A common shares of Cricut, Inc., valued at approximately $296,400, through Goldman Sachs & Co. LLC. The proposed sale is expected around August 4, 2026, on NASD. The …

Crinetics Pharmaceuticals (CRNX) On Vertex Deal Optimism And Results Looks Nearly Fully Valued

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Crinetics Pharmaceuticals (CRNX) is in focus after reporting second quarter 2026 results that paired …

Strata Critical Medical Q2 Results: Revenue Jumps 60.7% YoY

Cricut Releases Q2 2026 Financial Report in SEC 10-Q Filing

Cricut, Inc. (NASDAQ: CRCT) filed its Q2 2026 10-Q report with the SEC, covering the fiscal quarter ending June 30, 2026. Key details include the outstanding shares of Class A and Class B common stock, the company's classification as an accelerated filer, and its …

Cricut, Inc. Reports Second Quarter 2026 Financial Results

Cricut, Inc. announced its second-quarter 2026 financial results, reporting $156.3 million in revenue, a 9% decrease from Q2 2025, but a 59% increase in net income to $39.1 million. The company grew its paid subscribers to over 3.1 million, up 3% year-over-year, and saw …

Vertex Pharmaceuticals' Solid Q2, Raised Outlook Underscore Core Business Strength, RBC Says

Vertex Pharmaceuticals (VRTX) reported a solid Q2 and raised its outlook, highlighting the strength PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a …

Crinetics Pharmaceuticals (NASDAQ:CRNX) Hits New 52-Week High After Better-Than-Expected Earnings

Crispr Therapeutics Posts "Quiet" Quarter as Casgevy Advances, SiRNA Data Readouts Near, RBC Says

Crispr Therapeutics (CRSP) reported a relatively quiet Q2, with Casgevy continuing to gain commercia PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a …

Strata Critical Medical (NASDAQ: SRTA) grows revenue but posts Q2 loss

CRISPR Therapeutics' Q2 Earnings & Revenues Surpass Estimates

CRISPR Therapeutics (CRSP) reported a narrower-than-expected loss of 94 cents per share for Q2 2026, surpassing the Zacks Consensus Estimate of a $1.10 loss. The company's total revenues also exceeded expectations, reaching $10.2 million against an estimate of $7 million, driven by strong collaboration …

VRTX's Q2 Earnings Lag Estimates, Revenues Top, 2026 Sales View Raised

Vertex Pharmaceuticals VRTX reported adjusted earnings of $4.73 per share for the second quarter of 2026, missing the Zacks Consensus Estimate of $4.79. Earnings, however, rose around 4.6% year over year on higher product revenues. Second-quarter total revenues of $3.33 billion beat the Zacks …

Cricut (CRCT) holder files to sell 60,000 Class A shares under Rule 144

A shareholder of Cricut, Inc. (CRCT), Ashish Arora, has filed a notice under Rule 144 to sell up to 60,000 Class A Common Stock shares. The sale, valued at approximately $364,200, is expected to occur on August 5, 2026, through Goldman Sachs & Co. …

Strata Critical Medical Releases Q2 2026 Financial Results

Strata Critical Medical (NASDAQ: SRTA) reported its Q2 2026 financial results, with diluted EPS of -$0.12, missing the $0.01 estimate. Despite a 60.7% increase in revenue to $72.5M year-over-year, the company experienced a net loss of $10.5M, widening its per-share loss from Q2 2025. …

Vertex Pharmaceuticals Incorporated Q2 2026 Earnings Call Summary

Vertex Pharmaceuticals Incorporated Q2 2026 Earnings Call Summary - Moby Strategic Execution and Portfolio Expansion Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap …

Vertex (VRTX) Buys Crinetics To Push Beyond Cystic Fibrosis

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Vertex Pharmaceuticals (NasdaqGS:VRTX) has agreed to acquire Crinetics Pharmaceuticals in a deal expected to …

Strata Critical Medical Reports Q2 2026 Revenue Up 60.7% to $72.5M; Adjusted EBITDA $7.9M

Strata Critical Medical (SRTA) reported a significant revenue increase of 60.7% year-over-year, reaching $72.5 million in Q2 2026, primarily driven by the expansion of its Clinical business. The company posted an Adjusted EBITDA of $7.9 million (10.9% margin) and a GAAP net loss of …

Blade Air Mobility reports mixed Q2 results; updates FY26 outlook

* Blade Air Mobility press release [https://seekingalpha.com/pr/20605368-strata-critical-medical-announces-second-quarter-2026-results] (SRTA [https://seekingalpha.com/symbol/SRTA]): Q2 GAAP EPS of -$0.12 misses by $0.10. * Revenue of $72.51M (+60.7% Y/Y) beats by $4.9M. * _Adjusted EBITDA__(1)__ of $7.9 million in Q2 2026; Adjusted EBITDA margin of 10.9%_ * _Cash flow from …

European Lithium (ASX:EUR) Gains as Critical Metals Scheme Nears Its Vote

Criteo SA (CRTO) Q2 2023 Earnings Report - Results, Call & Slides

Criteo SA (CRTO) has released its Q2 2023 earnings report, exceeding analyst expectations. The company reported actual EPS of CHF0.40 against a consensus of CHF0.35, and actual revenue of CHF379.88M, significantly beating the expected CHF187.24M. However, year-over-year revenue growth showed a decline of 5.28%.

Crinetics Reports Wider Q2 Loss; Withdraws Guidance Ahead Of Company's Acquisition

(RTTNews) - Crinetics Pharmaceuticals, Inc. (CRNX) reported a wider net loss for the second quarter ended June 30, 2026, and also provided various business highlights. The company recently began generating revenue with the commercial launch of PALSONIFY (Paltusotine) for acromegaly. Company Profile Crinetics Pharmaceuticals …

Crinetics Pharmaceuticals (CRNX) Stock Looks Pricey As Buyout News Lands

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Crinetics Pharmaceuticals stock has delivered very strong gains over the past few years, yet the current valuation checks point to a market price …

Carter’s Inc. Names Tinuiti Full-Funnel Agency of Record to Drive Brand and Performance Growth

Carter’s Inc. has appointed Tinuiti as its Full-Funnel Agency of Record for all its brands in the U.S. and Canada. Tinuiti will leverage its proprietary Bliss Point technology to unify Carter's brand and performance investments, providing clarity across its media portfolio and connecting investments …

Crizac Q1 results FY27: PAT Rs 46 Cr, Revenue Rs 201 Cr

Strata Critical Medical earnings missed by $0.09, revenue topped estimates

Crinetics Pharmaceuticals, Inc. (CRNX) Stock Analysis: Revenue Growth Surges by 2,873% Amidst Strong Biotech Potential

Crimson Tide hails return to profit following “period of significant change”

Cricut Q2 Earnings Call Highlights

Cricut (CRCT) Earnings Date and Reports 2026 $CRCT

E.W. Scripps (SSP) Q2 Earnings Report Preview: What To Look For

Is Crinetics Pharmaceuticals (CRNX) Undervalued After Q2 Earnings Miss? GF Score: 47/100, Revenue at $25.1M

Crinetics (Nasdaq: CRNX) agrees to $85 cash-per-share sale to Vertex

Crinetics Pharmaceuticals announced it has agreed to be acquired by Vertex Pharmaceuticals for $85.00 per share in cash, totaling approximately $10.0 billion, or $8.8 billion net of estimated cash acquired. The acquisition is expected to close in the third quarter of 2026, pending regulatory …

Crispr Therapeut (CRSP) Stock News & Updates

This page provides news and updates for Crispr Therapeutics (CRSP), a company focused on gene-based medicines. Recent updates include a Q2 2026 financial report showing $76 million in CASGEVY revenue and advancements in multiple clinical programs. The company also announced participation in several investor …

CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Tops Revenue Estimates

CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $0.94 per share versus the Zacks Consensus Estimate of a loss of $1.1. This compares to a loss of $1.29 per share a year ago. These figures are adjusted for non-recurring items. This …